RayKnowChina Research Map
Shortlist

WuhanWuhan University

Renmin Hospital of Wuhan University

武汉大学人民医院

Listed for 19 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Renmin Hospital of Wuhan University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌13 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌12 papers led2 open trials led
  3. Hepatocellular carcinoma肝细胞癌87 papers led
  4. Stomach cancer胃癌74 papers led1 open trial led
  5. Retinoblastoma视网膜母细胞瘤5 papers led
  6. Osteosarcoma骨肉瘤31 papers led
  7. Gastrointestinal stromal tumour胃肠道间质瘤2 papers led
  8. Neuroblastoma神经母细胞瘤10 papers led
  9. Ewing sarcoma尤文肉瘤1 paper led
  10. Myasthenia gravis重症肌无力0 papers led
  11. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎1 paper led
  12. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  13. Amyotrophic lateral sclerosis肌萎缩侧索硬化症3 papers led
  14. Behçet disease白塞病2 papers led
  15. Alport syndromeAlport 综合征0 papers led
  16. IgA nephropathyIgA 肾病2 papers led
  17. Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
  18. Familial adenomatous polyposis家族性腺瘤性息肉病2 papers led
  19. Leber hereditary optic neuropathyLeber 遗传性视神经病变2 papers led

Not listed for: Hepatoblastoma, Chordoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Moyamoya disease, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 13 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.5%.

Papers led
13
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 5520232024: 1120242025: 112025

6 hospitals in Wuhan for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06749899

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 17 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xiamen, Zhongshan

  2. Recruiting
    Immune Score Based Radiomics in Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2021-11
    Registry
    NCT05126160

    Age 18 years to 70 years (registered criteria)

    Led by Zhejiang Cancer Hospital; 4 listed hospitals as study sitesHangzhou, Ningbo, Wenzhou, Wuhan

  3. Recruiting
    A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
    Phase
    Phase 1
    Started
    2021-11
    Registry
    NCT05194982

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chongqing, Guangzhou, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & AIRecurrent / metastatic diseaseRadiotherapy technique
Departments in papersENT / head & neck surgery

Over half of these papers are lab or animal studies.

Papers it led13
  1. Homing Effect Directed Cuprous Delivery Activates Cuproptosis Against Nasopharyngeal Carcinoma and Metastasis.2026Small (Weinheim an der Bergstrasse, Germany)
  2. Molecular network analysis of CPEB4 translational control and targeting CPEB4/β-catenin to modulate invasion and migration of nasopharyngeal carcinoma cells.2025International journal of medical sciencesFree full text
  3. CENPN suppresses autophagy and increases paclitaxel resistance in nasopharyngeal carcinoma cells by inhibiting the CREB-VAMP8 signaling axis.2024AutophagyFree full text
  4. Predicting prognosis of nasopharyngeal carcinoma based on deep learning: peritumoral region should be valued.2023Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  5. Deep Learning for Predicting Distant Metastasis in Patients with Nasopharyngeal Carcinoma Based on Pre-Radiotherapy Magnetic Resonance Imaging.2023Combinatorial chemistry & high throughput screeningFree full text
  6. MiR-3612 targeting THBS1 suppresses nasopharyngeal carcinoma progression by PI3K/AKT signaling pathway.2023Human & experimental toxicology
  7. Enhancing nasopharyngeal carcinoma cell radiosensitivity by suppressing AKT/mTOR via CENP-N knockdown.2023Journal of translational medicineFree full text
  8. Regorafenib inhibits growth, survival and angiogenesis in nasopharyngeal carcinoma and is synergistic with Mcl-1 inhibitor.2023The Journal of pharmacy and pharmacology
  9. (S,R)3-(4-Hydroxyphenyl)-4,5-Dihydro-5-Isoxazole Acetic Acid Methyl Ester Inhibits Epithelial-to-Mesenchymal Transition Through TGF-β/Smad4 Axis in Nasopharyngeal Carcinoma.2022Anti-cancer agents in medicinal chemistry
  10. Deep learning for locally advanced nasopharyngeal carcinoma prognostication based on pre- and post-treatment MRI.2022Computer methods and programs in biomedicine
  11. LncRNA FAM225A activates the cGAS-STING signaling pathway by combining FUS to promote CENP-N expression and regulates the progression of nasopharyngeal carcinoma.2022Pathology, research and practice
  12. Overexpression of Notch2 enhances radiosensitivity via inhibition of the AKT/mTOR signaling pathway in nasopharyngeal carcinoma.2021BioengineeredFree full text
  13. Ginkgolic Acid Suppresses Nasopharyngeal Carcinoma Growth by Inducing Apoptosis and Inhibiting AKT/NF-κB Signaling.2021Journal of medicinal food
All its trials on ClinicalTrials.gov, any status4
  1. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.RecruitingNCT06749899Study sitePhase 3Start 2025-05
  2. A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid TumorRecruitingNCT05194982Study sitePhase 1Start 2021-11
  3. Immune Score Based Radiomics in Nasopharyngeal CarcinomaRecruitingNCT05126160Study siteStart 2021-11
  4. Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)Active, not recruitingNCT05587374Study sitePhase 3Start 2023-08
More papers found outside PubMed (not counted)16
  1. 710P Mapping the disparity of nasopharyngeal carcinoma burden across 34 provinces in China, 1990-2040, forecasts with scenarios simulation using deep-learning algorithm2025Annals of Oncologyarticle
  2. Evaluation of Trident network against atlas and 2D U-net methods for auto-segmentation of organs at risk in nasopharyngeal carcinoma: a comparative study2025Frontiers in Physicsarticle
  3. Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma2022Figsharedataset
  4. Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  5. Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  6. Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  7. Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  8. Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  9. Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  10. Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  11. Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  12. Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  13. Boosting Advanced Nasopharyngeal Carcinoma Stage Prediction Using a Two-Stage Classification Framework Based on Deep Learning2021International Journal of Computational Intelligence Systemsarticle
  14. Correction to: Boosting Advanced Nasopharyngeal Carcinoma Stage Prediction Using a Two‑Stage Classification Framework Based on Deep Learning2021International Journal of Computational Intelligence Systemserratum
  15. Long Non-coding RNA PANDAR Promotes Radioresistance in Nasopharyngeal Carcinoma via SIRT1/Ku70/PI3K/Akt Pathway2021Research Squarepreprint
  16. S100A14 Induces Apoptosis and Negatively Regulates Proliferation of Nasopharyngeal Carcinoma Cells2021Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 12 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
12
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 4420232024: 1120242025: 442025

5 hospitals in Wuhan for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
    Phase
    Not given
    Started
    2023-05
    Registry
    NCT05894369

    Age 18 years to 80 years (registered criteria)

    Led by Renmin Hospital of Wuhan UniversityWuhan

  2. Recruiting
    A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 3
    Started
    2023-07
    Registry
    NCT05919030

    Age 18 years to Not stated (registered criteria)

    Led by Renmin Hospital of Wuhan UniversityWuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapyImmunotherapyNeoadjuvant & combined treatment
Departments in papersGastroenterology / hepatologyMedical oncology
Papers it led12
  1. Elaiophylin targets EIF4B to suppress the growth of esophageal squamous cell carcinoma via the PI3K/AKT signaling pathway.2025Cancer letters
  2. Porphyromonas gingivalis extracellular vesicles promotes tumor metastasis in esophageal squamous cell carcinoma by inducing PRKACB/JNK/ NFATC2 axis.2025Journal of nanobiotechnologyFree full text
  3. Immune Cellular Patterns Predicting Lymph Node Status Helps Personalized Management of Stage T1 Esophageal Squamous Cell Carcinoma.2025Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  4. Efficacy and Safety of Second-Line Immune Checkpoint Inhibitor Rechallenge in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study.2025Thoracic cancerFree full text
  5. A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread Across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy, and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.2024Annals of surgical oncology
  6. Human-Like Artificial Intelligent System for Predicting Invasion Depth of Esophageal Squamous Cell Carcinoma Using Magnifying Narrow-Band Imaging Endoscopy: A Retrospective Multicenter Study.2023Clinical and translational gastroenterologyFree full text
  7. Fusobacterium nucleatum promotes esophageal squamous cell carcinoma progression and chemoresistance by enhancing the secretion of chemotherapy-induced senescence-associated secretory phenotype via activation of DNA damage response pathway.2023Gut microbesFree full text
  8. Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  9. Fusobacterium nucleatum promotes proliferation in oesophageal squamous cell carcinoma via AHR/CYP1A1 signalling.2023The FEBS journal
  10. KISS-1, Mediated by Promoter Methylation, Suppresses Esophageal Squamous Cell Carcinoma Metastasis via MMP2/9/MAPK Axis.2022Digestive diseases and sciences
  11. Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma.2022JAMA network openFree full text
  12. Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: A propensity score matching and landmark analyses.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
All its trials on ClinicalTrials.gov, any status3
  1. A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT05919030Lead sponsorPhase 3Start 2023-07
  2. Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell CarcinomaRecruitingNCT05894369Lead sponsorStart 2023-05
  3. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05
More papers found outside PubMed (not counted)13
  1. The Transcription Factor ELK1 Promotes Esophageal Squamous Cell Carcinoma Progression by Activating the CDK4/Wnt/β-catenin Pathway2025Journal of Biological Regulators and Homeostatic Agents/Journal of Biological Regulators & Homeostatic Agentsarticle
  2. Novel Roles of HOXD11 and HOXD13 in Mediating Response to Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma2024International Journal of Radiation Oncology*Biology*Physicsarticle
  3. Prediction of lymph node status in stage T1 esophageal squamous cell carcinoma.2024Journal of Clinical Oncologyconference-abstract
  4. A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma2023International Journal of Radiation Oncology*Biology*Physicsarticle
  5. A prospective clinical trial of camrelizumab in combination with chemoradiotherapy in patients with metastatic esophageal squamous cell carcinoma.2022Journal of Clinical Oncologyconference-abstract
  6. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figsharedataset
  7. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figsharedataset
  8. Prognosis and Benefit Factors of Definitive Concurrent Chemoradiotherapy for Patients with Oligometastatic Esophageal Squamous Cell Carcinoma2022International Journal of Radiation Oncology*Biology*Physicsarticle
  9. Relationship between ENO1 and Metastasis Risk and Prognosis in Esophageal squamous cell carcinoma2022Research Squarepreprint
  10. Clinical Parameters Predicting Prognosis for Elderly Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma2021International Journal of Radiation Oncology*Biology*Physicsarticle
  11. Elaiophylin Targets EIF4B to Regulate the Proliferation, Invasion, and Apoptosis of Esophageal Squamous Cancer Cells via the PI3K/AKT Signaling Pathway2021Research Squarepreprint
  12. Elaiophylin Targets EIF4B to Regulate the Proliferation, Invasion, and Apoptosis of Esophageal Squamous Cell Carcinoma via the PI3K/AKT Signaling Pathway2021Research Squarepreprint
  13. Elaiophylin Targets EIF4B to Regulate the Proliferation, Invasion, and Apoptosis of Esophageal Squamous Cell Carcinoma via the PI3K/AKT Signaling Pathway2021Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 87 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
87
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 101020212022: 171720222023: 262620232024: 191920242025: 14142025

6 hospitals in Wuhan for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyPathology / laboratory medicineMedical oncology
Papers it led87
  1. Matrix stiffening-driven hepatocellular carcinoma progression through OASL-mediated cGAS-STING repression and subsequent macrophage activation.2026International immunopharmacology
  2. Structurally diverse tetrahydroxanthone analogues from Paraconiothyrium sp. AC31 with pyroptosis induction through targeted inhibition of PARP1 in hepatocellular carcinoma cells.2025Bioorganic chemistry
  3. CYP8B1 inhibits hepatocellular carcinoma progression by repressing PAK4 transcription through inhibition of nuclear translocation of u-STAT1.2025Cell death & diseaseFree full text
  4. Splenic volume as a predictor of survival in cancer patients treated with immune checkpoint inhibitors.2025Frontiers in immunologyFree full text
  5. Comprehensive analysis of mitochondrial solute carrier family 25 (SLC25) identifies member 19 (SLC25A19) as a regulatory factor in hepatocellular carcinoma.2025Gene
  6. The prognostic significance and potential mechanism of PFDN4 in hepatocellular carcinoma.2025International immunopharmacology
  7. NSMCE2 promotes the occurrence and development of HCC by regulating the SUMOylation of PPARα.2025International immunopharmacology
  8. Multi-Omics Integration: Predicting Progression and Optimizing Clinical Treatment of Hepatocellular Carcinoma Through Malignant-Cell-Related Genes.2025International journal of molecular sciencesFree full text
  9. Extracellular vesicle digital scoring assay for assessment of treatment responses in hepatocellular carcinoma patients.2025Journal of experimental & clinical cancer research : CRFree full text
  10. Metal-organic framework nanoparticles activate cGAS-STING pathway to improve radiotherapy sensitivity.2025Journal of nanobiotechnologyFree full text
  11. m6A-modified circCCAR1 promotes malignant proliferation by enhancing KIF5B expression in hepatocellular carcinoma.2025Journal of physiology and biochemistry
  12. m6A regulators-based gene expression pattern is associated with immune microenvironment characteristics in hepatocellular carcinoma.2025Scientific reportsFree full text
  13. Single-cell landscape of dynamic changes in CD8+ T cells, CD4+ T cells and exhausted T cells in hepatocellular carcinoma.2025Scientific reportsFree full text
  14. Nanodelivery of Y-27632 by RGD-modified liposome enhances radioimmunotherapy of hepatocellular carcinoma via tumor microenvironment matrix stiffness reprogramming.2025TheranosticsFree full text
  15. The Role of HBx Mutations in Chronic Hepatitis B with Acute Exacerbation.2025VirusesFree full text
  16. Prognostic impact of body composition in hepatocellular carcinoma patients with immunotherapy.2024Annals of medicineFree full text
  17. C-X-C motif chemokine receptor 4 inhibition promotes the effect of plantamajoside in hepatocellular carcinoma.2024Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology
  18. Matrix stiffness-related extracellular matrix signatures and the DYNLL1 protein promote hepatocellular carcinoma progression through the Wnt/β-catenin pathway.2024BMC cancerFree full text
  19. Knockdown of SLC16A3 decreases extracellular lactate concentration in hepatocellular carcinoma, alleviates hypoxia and induces ferroptosis.2024Biochemical and biophysical research communications
  20. USP30 promotes the progression of breast cancer by stabilising Snail.2024Cancer gene therapyFree full text
  21. Impact of inflammation and the immune system on hepatocellular carcinoma recurrence after hepatectomy.2024Cancer medicine
  22. A Novel Cholesterol Metabolism-Related lncRNA Signature Predicts the Prognosis of Patients with Hepatocellular Carcinoma and Their Response to Immunotherapy.2024Frontiers in bioscience (Landmark edition)
  23. IGFALS suppresses hepatocellular carcinoma progression by stabilizing PPAR-γ.2024International immunopharmacology
  24. Dihydroartemisinin remodels tumor micro-environment and improves cancer immunotherapy through inhibiting cyclin-dependent kinases.2024International immunopharmacology
  25. S100A16 is a potential target for reshaping the tumor microenvironment in the hypoxic context of liver cancer.2024International immunopharmacology
  26. Association between ascites Gustave Roussy immune score and the intratumoural microbiome in malignant ascites secondary to hepatocellular carcinoma.2024International immunopharmacology
  27. A review of deep learning approaches for multimodal image segmentation of liver cancer.2024Journal of applied clinical medical physicsFree full text
  28. Deciphering the molecular interplay and tumorigenesis in hepatocellular carcinoma through insights into FBXL6 and KRASG12D.2024Military Medical ResearchFree full text
  29. Transcription factor RELA promotes hepatocellular carcinoma progression by promoting the transcription of m6A modulator METTL3.2024Pathology, research and practice
  30. Novel application of the ferroptosis-related genes risk model associated with disulfidptosis in hepatocellular carcinoma prognosis and immune infiltration.2024PeerJFree full text
  31. High tumor burden score indicated the unfavorable prognosis in patients with hepatocellular carcinoma: A meta-analysis.2024PloS oneFree full text
  32. Serum ApoB/ApoA1 ratio in patients with CHB and the occurrence of HBV related cirrhosis and HBV related hepatocellular carcinoma.2024Scientific reportsFree full text
  33. The prognostic significance and potential mechanism of DBF4 zinc finger in hepatocellular carcinoma.2024Scientific reportsFree full text
  34. Ascitic microbiota alteration is associated with portal vein tumor thrombosis occurrence and prognosis in hepatocellular carcinoma.2024mBioFree full text
  35. Apoprotein E methylation is correlated with immune microenvironment in hepatocellular carcinoma.2023Acta oncologica (Stockholm, Sweden)
  36. Prognostic value and immunological role of CSNK1D in human cancers.2023AgingFree full text
  37. A comprehensive survival and prognosis analysis of GPR55 expression in hepatocellular carcinoma.2023AgingFree full text
  38. Construction of a T-cell exhaustion-related gene signature for predicting prognosis and immune response in hepatocellular carcinoma.2023AgingFree full text
  39. ATP6V1F is a novel prognostic biomarker and potential immunotherapy target for hepatocellular carcinoma.2023BMC medical genomicsFree full text
  40. Basement membrane-related regulators for prediction of prognoses and responses to diverse therapies in hepatocellular carcinoma.2023BMC medical genomicsFree full text
  41. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq data reveals dynamic changes in tumor-associated neutrophils in the tumor microenvironment of hepatocellular carcinoma and leads to the establishment of a neutrophil-related prognostic mo2023Cancer immunology, immunotherapy : CIIFree full text
  42. An exploratory clinical trial of apatinib combined with intensity-modulated radiation therapy for patients with unresectable hepatocellular carcinoma.2023Cancer medicineFree full text
  43. GNB1 promotes hepatocellular carcinoma progression by targeting BAG2 to activate P38/MAPK signaling.2023Cancer scienceFree full text
  44. USP25 promotes hepatocellular carcinoma progression by interacting with TRIM21 via the Wnt/β-catenin signaling pathway.2023Chinese medical journalFree full text
  45. FOXK2 affects cancer cell response to chemotherapy by promoting nucleotide de novo synthesis.2023Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  46. Targeting WDxR motif reprograms immune microenvironment and inhibits hepatocellular carcinoma progression.2023EMBO molecular medicineFree full text
  47. Nomogram model for predicting esophsagogastric varices in hepatocellular carcinoma with cirrhosis.2023European journal of gastroenterology & hepatology
  48. Construction and validation of a nomogram for patients with multiple hepatocellular carcinoma: A SEER-based study.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  49. KIFC3 regulates progression of hepatocellular carcinoma via EMT and the AKT/mTOR pathway.2023Experimental cell research
  50. Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies.2023International immunopharmacology
  51. High intramuscular adipose tissue content associated with prognosis and postoperative complications of cancers.2023Journal of cachexia, sarcopenia and muscleFree full text
  52. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on NK cell marker genes to predict prognosis and immunotherapy response in hepatocellular carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  53. The application of nanoparticles in immunotherapy for hepatocellular carcinoma.2023Journal of controlled release : official journal of the Controlled Release Society
  54. Decreased propionyl-CoA metabolism facilitates metabolic reprogramming and promotes hepatocellular carcinoma.2023Journal of hepatology
  55. Recent updates on targeting the molecular mediators of NAFLD.2023Journal of molecular medicine (Berlin, Germany)
  56. Characterization of the intestinal fungal microbiome in patients with hepatocellular carcinoma.2023Journal of translational medicineFree full text
  57. Evaluation of Serum FGL1 as Diagnostic Markers for HBV-Related Hepatocellular Carcinoma.2023Laboratory medicine
  58. Two fragments of HBV DNA integrated into chrX: 11009033 and its genetic regulation in HepG2.2.15.2023Molecular medicine reportsFree full text
  59. Construction and validation of 3-genes hypoxia-related prognostic signature to predict the prognosis and therapeutic response of hepatocellular carcinoma patients.2023PloS oneFree full text
  60. Characteristics of lactate metabolism phenotype in hepatocellular carcinoma.2023Scientific reportsFree full text
  61. Genes Modulating Butyrate Metabolism for Assessing Clinical Prognosis and Responses to Systematic Therapies in Hepatocellular Carcinoma.2022BiomoleculesFree full text
  62. PSMD12 promotes the activation of the MEK-ERK pathway by upregulating KIF15 to promote the malignant progression of liver cancer.2022Cancer biology & therapyFree full text
  63. Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody.2022Cancer control : journal of the Moffitt Cancer CenterFree full text
  64. USF2-mediated upregulation of TXNRD1 contributes to hepatocellular carcinoma progression by activating Akt/mTOR signaling.2022Cell death & diseaseFree full text
  65. Differential expression of insulin-like growth factor type 1 receptor identifies heterogeneous intrahepatic regulatory T subsets in mouse hepatocellular carcinoma.2022Clinical and experimental immunology
  66. RMI2 is a prognostic biomarker and promotes tumor growth in hepatocellular carcinoma.2022Clinical and experimental medicine
  67. A Novel Ferroptosis-Related Signature for Prediction of Prognosis, Immune Profiles and Drug Sensitivity in Hepatocellular Carcinoma Patients.2022Current oncology (Toronto, Ont.)Free full text
  68. Low-grade hepatocellular carcinoma characteristics, a practical nomogram and risk stratification system: a SEER population-based study.2022Expert review of gastroenterology & hepatology
  69. The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors.2022Frontiers in immunologyFree full text
  70. Comprehensive Analysis Identifies and Validates the Tumor Microenvironment Subtypes to Predict Anti-Tumor Therapy Efficacy in Hepatocellular Carcinoma.2022Frontiers in immunologyFree full text
  71. Identification and Analysis of Immune-Related Gene Signature in Hepatocellular Carcinoma.2022GenesFree full text
  72. Letter to the Editor: Serum bioavailable 25-hydroxyvitamin D levels correlate with hepatocellular carcinoma survival.2022Hepatology (Baltimore, Md.)
  73. Declining disease burden of HCC in the United States, 1992-2017: A population-based analysis.2022Hepatology (Baltimore, Md.)
  74. CircRNA_0040705 promotes the progression of hepatocellular carcinoma.2022IUBMB life
  75. Protein succinylation associated with the progress of hepatocellular carcinoma.2022Journal of cellular and molecular medicineFree full text
  76. Research Progress in Alpha-fetoprotein-induced Immunosuppression of Liver Cancer.2022Mini reviews in medicinal chemistry
  77. ROS-Related miRNAs Regulate Immune Response and Chemoradiotherapy Sensitivity in Hepatocellular Carcinoma by Comprehensive Analysis and Experiment.2022Oxidative medicine and cellular longevityFree full text
  78. ADAM15 correlates with prognosis, immune infiltration and apoptosis in hepatocellular carcinoma.2021AgingFree full text
  79. Identification of a Nine Immune-Related lncRNA Signature as a Novel Diagnostic Biomarker for Hepatocellular Carcinoma.2021BioMed research internationalFree full text
  80. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients2021Clinics and research in hepatology and gastroenterology
  81. Long non-coding RNA LINC00630 facilitates hepatocellular carcinoma progression through recruiting transcription factor E2F1 to up-regulate cyclin-dependent kinase 2 expression.2021Human & experimental toxicology
  82. Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis.2021International immunopharmacology
  83. Evaluation of Serum GDF15, AFP, and PIVKA-II as Diagnostic Markers for HBV-Associated Hepatocellular Carcinoma.2021Laboratory medicine
  84. Immune-related microRNA signature for predicting prognosis and the immune microenvironment in hepatocellular carcinoma.2021Life sciences
  85. Downregulation of CYP39A1 Serves as a Novel Biomarker in Hepatocellular Carcinoma with Worse Clinical Outcome.2021Oxidative medicine and cellular longevityFree full text
  86. System Analysis of ROS-Related Genes in the Prognosis, Immune Infiltration, and Drug Sensitivity in Hepatocellular Carcinoma.2021Oxidative medicine and cellular longevityFree full text
  87. Sorafenib blocks the activation of the HIF-2α/VEGFA/EphA2 pathway, and inhibits the rapid growth of residual liver cancer following high-intensity focused ultrasound therapy in vivo.2021Pathology, research and practice
Chinese-language papers (not in the count)2
  1. [Hepatoid adenocarcinoma of the stomach metastatic to liver: a clinicopathological analysis of 3 cases].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [Primary hepatoid adenocarcinoma in lung, gallbladder and bladder: a clinicopathological observation of three cases].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status2
  1. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblationCompletedNCT04102098Study sitePhase 3Start 2019-12
  2. Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular CarcinomaTerminatedNCT03349255Study sitePhase 1Start 2017-10

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 74 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.8%.

Papers led
74
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 212120212022: 9920222023: 141420232024: 131320242025: 15152025

5 hospitals in Wuhan for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Samples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant Disease
    Phase
    Not given
    Started
    2020-12
    Registry
    NCT03972956

    Age 18 years to 80 years (registered criteria)

    Led by Renmin Hospital of Wuhan UniversityWuhan

  2. Recruiting
    Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
    Phase
    Not given
    Started
    2026-02
    Registry
    NCT07401199

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShijiazhuang, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEarly detection & endoscopyImaging & AIImmunotherapy & targeted drugs
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Medical oncologyPathology / laboratory medicine
Papers it led74
  1. Artificial intelligence assistance narrows the experience gap in endoscopic reporting of gastric lesions: a prospective clinical trial.2026Surgical endoscopyFree full text
  2. Efficacy of endoscopic therapy in patients with T1b gastric cancer and construction of a prognostic prediction model: a retrospective cohort study and multicenter validation study.2026Surgical endoscopyFree full text
  3. Amylin inhibits gastric cancer progression by targeting CCN1 and affecting the PI3K/AKT signalling pathway.2025Annals of medicineFree full text
  4. Global status and attributable risk factors of esophageal, stomach, colorectal cancers in adolescents and young adults: global burden of disease 2021 study analysis.2025BMC cancerFree full text
  5. Clinical implications of DNA ploidy, stroma, and nucleotyping in predicting peritoneal metastasis risk for gastric cancer.2025BMC cancerFree full text
  6. Development and verification of a radiomics model to forecast Ki67 index and prognosis in advanced gastric tubular adenocarcinoma.2025BMC gastroenterologyFree full text
  7. Screening and surveillance of hereditary upper GI cancers.2025Best practice & research. Clinical gastroenterology
  8. LncRNA FIRRE drives gastric cancer progression via ZFP64-mediated TUBB3 promoter activation.2025Cancer letters
  9. Comprehensive proteomic analysis and multidimensional model construction of peritoneal metastasis in gastric cancer.2025Cancer letters
  10. SIRT1 Expression in Human Gastrointestinal Tumors and Its Clinical Significance.2025Cancer medicineFree full text
  11. Clinical decision tree for optimizing endoscopic assessment of signet ring cell carcinoma in hereditary diffuse gastric cancer surveillance.2025Endoscopy
  12. The mechanism of Weiqi decoction treating gastric cancer: a work based on network pharmacology and experimental verification.2025HereditasFree full text
  13. Trends in Stomach Cancer Burden in China: A Joinpoint and APC Analysis Based on GBD 2021.2025Journal of gastroenterology and hepatologyFree full text
  14. Integrated Genomic Analysis Identifies Clinically Relevant Molecular Subtypes and Disulfidptosis-Related Prognostic Signature of Gastric Cancer.2025Journal of immunotherapy (Hagerstown, Md. : 1997)
  15. A prognostic model for gastric cancer constructed by multiple machine learning algorithms.2025Journal of molecular histology
  16. First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis.2025Molecular cancer therapeutics
  17. Advancements in non-invasive diagnosis of gastric cancer.2025World journal of gastroenterologyFree full text
  18. Integrated multi-omics analysis and machine learning identify hub genes and potential mechanisms of resistance to immunotherapy in gastric cancer.2024AgingFree full text
  19. System-wide identification of novel de-ubiquitination targets for USP10 in gastric cancer metastasis through multi-omics screening.2024BMC cancerFree full text
  20. TRIM47 drives gastric cancer cell proliferation and invasion by regulating CYLD protein stability.2024Biology directFree full text
  21. Sarcopenia affects the clinical efficacy of immune checkpoint inhibitors in patients with gastrointestinal cancers.2024Clinical nutrition (Edinburgh, Scotland)
  22. An artificial intelligence system for chronic atrophic gastritis diagnosis and risk stratification under white light endoscopy.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  23. Co-Expression Network Analysis and Molecular Docking Demonstrate That Diosgenin Inhibits Gastric Cancer Progression via SLC1A5/mTORC1 Pathway.2024Drug design, development and therapyFree full text
  24. Macrophages enhance cisplatin resistance in gastric cancer through the transfer of circTEX2.2024Journal of cellular and molecular medicineFree full text
  25. Gastric neoplasm detection of computer-aided detection-assisted esophagogastroduodenoscopy changes with implement scenarios: a real-world study.2024Journal of gastroenterology and hepatology
  26. The effect of incorporating domain knowledge with deep learning in identifying benign and malignant gastric whitish lesions: A retrospective study.2024Journal of gastroenterology and hepatology
  27. Pterostilbene suppresses gastric cancer proliferation and metastasis by inhibiting oncogenic JAK2/STAT3 signaling: In vitro and in vivo therapeutic intervention.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  28. Role of ATP citrate lyase and its complementary partner on fatty acid synthesis in gastric cancer.2024Scientific reportsFree full text
  29. A risk prediction model for delayed bleeding after ESD for gastric precancerous lesions.2024Surgical endoscopy
  30. Double-nylon purse-string suture in closing postoperative wounds following endoscopic resection of large (≥ 3 cm) gastric submucosal tumors.2024World journal of gastroenterologyFree full text
  31. Identification of GNG7 as a novel biomarker and potential therapeutic target for gastric cancer via bioinformatic analysis and in vitro experiments.2023AgingFree full text
  32. Baicalin enhances the efficacy of 5-Fluorouracil in gastric cancer by promoting ROS-mediated ferroptosis.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  33. Age-specific cardiovascular disease-related mortality among patients with major gastrointestinal cancers: A SEER population-based study.2023Cancer medicineFree full text
  34. Special AT-rich sequence binding protein 1 promotes multidrug resistance in gastric cancer by regulation of Ezrin to alter subcellular localization of ATP-binding cassette transporters.2023Cancer scienceFree full text
  35. Identifying the key genes of Epstein-Barr virus-regulated tumour immune microenvironment of gastric carcinomas.2023Cell proliferationFree full text
  36. KIFC3 Regulates the progression and metastasis of gastric cancer via Notch1 pathway.2023Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  37. A deep-learning based system using multi-modal data for diagnosing gastric neoplasms in real-time (with video).2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  38. CircSOD2 polarizes macrophages towards the M1 phenotype to alleviate cisplatin resistance in gastric cancer cells by targeting the miR-1296/STAT1 axis.2023Gene
  39. The Use of Antibiotics During Immune Checkpoint Inhibitor Treatment Is Associated with Lower Survival in Advanced Esophagogastric Cancer.2023International immunopharmacology
  40. Exploring the challenge of early gastric cancer diagnostic AI system face in multiple centers and its potential solutions.2023Journal of gastroenterology
  41. Thymoquinone induces apoptosis and protective autophagy in gastric cancer cells by inhibiting the PI3K/Akt/mTOR pathway.2023Phytotherapy research : PTR
  42. Targeted labeling with tissue marking dyes guided by magnifying endoscopy of endoscopic submucosal dissection specimen improves the accuracy of endoscopic and histopathological diagnosis of early gastric cancer: a before-after study.2023Surgical endoscopy
  43. The effectiveness of a computer-aided system in improving the detection rate of gastric neoplasm and early gastric cancer: study protocol for a multi-centre, randomized controlled trial.2023TrialsFree full text
  44. Comparison of Helicobacter pylori positive and negative gastric cancer via multi-omics analysis.2023mBioFree full text
  45. Key Molecules of Fatty Acid Metabolism in Gastric Cancer.2022BiomoleculesFree full text
  46. Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody.2022Cancer control : journal of the Moffitt Cancer CenterFree full text
  47. miR-137 Modulates Human Gastric Cancer Cell Proliferation, Apoptosis, and Migration by Targeting EZH2.2022Critical reviews in eukaryotic gene expression
  48. Real-time use of artificial intelligence for diagnosing early gastric cancer by magnifying image-enhanced endoscopy: a multicenter diagnostic study (with videos).2022Gastrointestinal endoscopy
  49. Real-time artificial intelligence for detecting focal lesions and diagnosing neoplasms of the stomach by white-light endoscopy (with videos).2022Gastrointestinal endoscopy
  50. Deep learning system compared with expert endoscopists in predicting early gastric cancer and its invasion depth and differentiation status (with videos).2022Gastrointestinal endoscopy
  51. The Application of Two-Stage Operation for High-Risk Patients with Oesophageal Cancer Following Gastrectomy.2022Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  52. Identifying novel therapeutic targets in gastric cancer using genome-wide CRISPR-Cas9 screening.2022Oncogene
  53. Paeonol inhibits the malignancy of Apatinib-resistant gastric cancer cells via LINC00665/miR-665/MAPK1 axis.2022Phytomedicine : international journal of phytotherapy and phytopharmacology
  54. Cell differentiation trajectory predicts patient potential immunotherapy response and prognosis in gastric cancer.2021AgingFree full text
  55. Long non-coding RNA LINC00511 regulates the expression of microRNA-625-5p and activates signal transducers and activators of transcription 3 (STAT3) to accelerate the progression of gastric cancer.2021BioengineeredFree full text
  56. MicroRNA-1269b inhibits gastric cancer development through regulating methyltransferase-like 3 (METTL3).2021BioengineeredFree full text
  57. Silencing of long non-coding RNA HCP5 inhibits proliferation, invasion, migration, and promotes apoptosis via regulation of miR-299-3p/SMAD5 axis in gastric cancer cells.2021BioengineeredFree full text
  58. Identification of a novel immune prognostic model in gastric cancer.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  59. Radiotherapy benefited the survival of patients with intestinal-type gastric adenocarcinoma: a SEER population-based study.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  60. Reconstruction of the esophagus of patients with middle thoracic esophageal carcinoma using the remnant stomach following Billroth II gastrectomy.2021Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  61. Accurate diagnosis and prognosis prediction of gastric cancer using deep learning on digital pathological images: A retrospective multicentre study.2021EBioMedicineFree full text
  62. Evaluation of the effects of an artificial intelligence system on endoscopy quality and preliminary testing of its performance in detecting early gastric cancer: a randomized controlled trial.2021EndoscopyRCT
  63. A deep learning-based system for identifying differentiation status and delineating the margins of early gastric cancer in magnifying narrow-band imaging endoscopy.2021Endoscopy
  64. MicroRNA-328-3p facilitates the progression of gastric cancer via KEAP1/NRF2 axis.2021Free radical research
  65. Propionibacterium acnes overabundance in gastric cancer promote M2 polarization of macrophages via a TLR4/PI3K/Akt signaling.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  66. Artificial intelligence in the diagnosis of gastric precancerous conditions by image-enhanced endoscopy: a multicenter, diagnostic study (with video).2021Gastrointestinal endoscopy
  67. Pyroptosis Patterns Characterized by Distinct Tumor Microenvironment Infiltration Landscapes in Gastric Cancer.2021GenesFree full text
  68. Having gastroesophageal cancer is associated with increased risk of severe COVID-19-related events in patients with digestive tract cancer: A multicenter, retrospective, cohort study.2021International journal of cancer
  69. Artificial intelligence in upper GI endoscopy - current status, challenges and future promise.2021Journal of gastroenterology and hepatology
  70. Proximal gastrectomy with double-tract reconstruction versus total gastrectomy for proximal early gastric cancer: A systematic review and meta-analysis.2021MedicineFree full text
  71. Identification of hub genes and construction of an mRNA-miRNA-lncRNA network of gastric carcinoma using integrated bioinformatics analysis.2021PloS oneFree full text
  72. Identification of stem cell-related subtypes and risk scoring for gastric cancer based on stem genomic profiling.2021Stem cell research & therapyFree full text
  73. The Clinicopathological Features and Overall Survival of Patients With Gastric Neuroendocrine Carcinoma.2021Technology in cancer research & treatmentFree full text
  74. Effect of a deep learning-based system on the miss rate of gastric neoplasms during upper gastrointestinal endoscopy: a single-centre, tandem, randomised controlled trial.2021The lancet. Gastroenterology & hepatologyRCT
Chinese-language papers (not in the count)3
  1. [Mucoepidermoid carcinoma of the stomach: report of two cases].2024Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [Hepatoid adenocarcinoma of the stomach metastatic to liver: a clinicopathological analysis of 3 cases].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  3. [Primary solid acinar rhabdomyosarcoma of stomach: report of a case].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status5
  1. Samples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant DiseaseRecruitingNCT03972956Lead sponsorStart 2020-12
  2. First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GCCompletedNCT06238752Lead sponsorPhase 2Start 2021-03
  3. Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)RecruitingNCT07401199Study siteStart 2026-02
  4. Development of a Multimodal AI System for GIST ManagementCompletedNCT07454967Study siteStart 2026-03
  5. Plasma Metabolic Biomarkers for Gastric Cancer DiagnosisCompletedNCT06109805Study siteStart 2023-10

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 5 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 1.7%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 1120232024: 0020242025: 112025

16 hospitals in Wuhan for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Over half of these papers are lab or animal studies.

Papers it led5
  1. Comprehensive analysis of single-cell and bulk RNA sequencing uncover tumor microenvironment diversity in invasive Retinoblastoma.2025Scientific reports
  2. Highly Efficient Photodynamic Therapy with Mitochondria-Targeting Aggregation-Induced Emission Photosensitizer for Retinoblastoma.2023Advanced healthcare materials
  3. GSDME Increases Chemotherapeutic Drug Sensitivity by Inducing Pyroptosis in Retinoblastoma Cells.2022Oxidative medicine and cellular longevity
  4. The anticancer effects of 7-Methoxyheptaphylline against the human retinoblastoma cells are facilitated via S-phase cell cycle arrest, mitochondrial apoptosis and inhibition of Wnt/β-catenin signalling pathway.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  5. The Results of Pars Plana Vitrectomy in the Treatment of Intraocular Retinoblastoma: A Retrospective Study and Literature Review.2021Technology in cancer research & treatment
Earlier papers (2016–2020)4
  1. Inhibition of anticancer growth in Retinoblastoma cells by naturally occurring sesquiterpene nootkatone is mediated via autophagy, endogenous ROS production, cell cycle arrest and inhibition of NF-κB signalling pathway.2020Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  2. The anticancer effects of 7-Methoxyheptaphylline against the human retinoblastoma cells are facilitated via S-phase cell cycle arrest, mitochondrial apoptosis and inhibition of Wnt/β-catenin signalling pathway.2020Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  3. Bioinformatics analysis of multi-omics data identifying molecular biomarker candidates and epigenetically regulatory targets associated with retinoblastoma.2020Medicine
  4. Temsirolimus as a dual inhibitor of retinoblastoma and angiogenesis via targeting mTOR signalling.2019Biochemical and biophysical research communications
All its trials on ClinicalTrials.gov, any status1
  1. A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of RetinoblastomaStatus unknownNCT04990271Study sitePhase 2Start 2021-07

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 31 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 1.4%.

Papers led
31
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 4420222023: 111120232024: 3320242025: 11112025

22 hospitals in Wuhan for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led31
  1. TRIM17 promotes the progression of osteosarcoma by regulating PDK1 m6A modification-mediated AKT/mTOR pathway activation through ubiquitination of FTO.2025Cell death & disease
  2. ABLIM1 promotes the proliferation, migration and invasion of osteosarcoma through DCC mediated activation of PI3K/AKT signaling pathway.2025Cellular signalling
  3. IRF2BPL inhibits proliferation, migration and invasion of osteosarcoma cells by inhibiting FOSL2-mediated PI3K/AKT pathway activation.2025Cellular signalling
  4. Bayesian Optimization-Enhanced Machine Learning for Osteosarcoma Risk Stratification Based on Sphingolipid Metabolism.2025Human mutation
  5. RNF207 promotes the proliferation, migration and invasion of osteosarcoma through KCNQ1 mediated activation of ERK/MEK signaling pathway.2025International immunopharmacology
  6. DUSP3 restrains the progression and stemness property of osteosarcoma through regulating EGFR/STAT3/SOX2 axis.2025International journal of biological sciences
  7. Bayesian-optimized deep learning for identifying essential genes of mitophagy and fostering therapies to combat drug resistance in human cancers.2025Journal of cellular and molecular medicine
  8. HMGCL activates autophagy in osteosarcoma through β-HB mediated inhibition of the PI3K/AKT/mTOR signaling pathway.2025Journal of translational medicine
  9. Research progress on cancer-associated fibroblasts in osteosarcoma.2025Oncology research
  10. Constructing a prognostic model for osteosarcoma based on centrosome-related genes and identifying potential therapeutic targets of paclitaxel.2025Scientific reports
  11. The homeobox family gene signature predicts the prognosis of osteosarcoma and correlates with immune invasion.2025Scientific reports
  12. ZNF692 promotes osteosarcoma cell proliferation, migration, and invasion through TNK2-mediated activation of the MEK/ERK pathway.2024Biology direct
  13. SLC38A5 suppresses ferroptosis through glutamine-mediated activation of the PI3K/AKT/mTOR signaling in osteosarcoma.2024Journal of translational medicine
  14. CGREF1 modulates osteosarcoma proliferation by regulating the cell cycle through the Wnt/β-catenin signaling pathway.2024Molecular medicine (Cambridge, Mass.)
  15. Incidental detection of Ewing sarcoma in the thoracic spinal cord by 18F-FDG PET/CT in a pediatric patient with cerebral infarction.2023Asian journal of surgery
  16. Construction of a prognostic risk score model based on the ARHGAP family to predict the survival of osteosarcoma.2023BMC cancer
  17. TRIM26 inhibited osteosarcoma progression through destabilizing RACK1 and thus inactivation of MEK/ERK signaling.2023Cell death & disease
  18. CircTNPO1 promotes the tumorigenesis of osteosarcoma by sequestering miR-578 to upregulate WNT5A expression.2023Cellular signalling
  19. Gambogenic acid induces cell death in human osteosarcoma through altering iron metabolism, disturbing the redox balance, and activating the P53 signaling pathway.2023Chemico-biological interactions
  20. CircUSP48 promotes malignant behavior by regulating CYR61 via miR-365 in osteosarcoma.2023Functional & integrative genomics
  21. METTL3-mediated m6A modification of circRNF220 modulates miR-330-5p/survivin axis to promote osteosarcoma progression.2023Journal of cancer research and clinical oncology
  22. Silencing circUSP48 suppresses osteosarcoma progression by regulating the miR-335/ smad nuclear interacting protein 1 pathway.2023Journal of clinical laboratory analysis
  23. Circadian rhythm-associated lncRNA RP11-414H17.5 as a key therapeutic target in osteosarcoma affects the tumor immune microenvironment and enhances malignancy.2023Journal of orthopaedic surgery and research
  24. RILP inhibits tumor progression in osteosarcoma via Grb10-mediated inhibition of the PI3K/AKT/mTOR pathway.2023Molecular medicine (Cambridge, Mass.)
  25. Identification and validation of long noncoding RNA AC083900.1 and RP11-283C24.1 for prediction of progression of osteosarcoma.2023Mutation research
  26. Silencing long non-coding RNA LINC00960 inhibits osteosarcoma proliferation by sponging miR-107 to downregulate SALL4.2022Biochemical and biophysical research communications
  27. Dissecting the effect of sphingolipid metabolism gene in progression and microenvironment of osteosarcoma to develop a prognostic signature.2022Frontiers in endocrinology
  28. Repurposing Ivermectin to augment chemotherapy's efficacy in osteosarcoma.2022Human & experimental toxicology
  29. Long non-coding RNA NR2F2-AS1 regulates human osteosarcoma growth and metastasis through miR-425-5p-mediated HMGB2.2022International journal of clinical oncology
  30. Human umbilical vein endothelial cells derived-exosomes promote osteosarcoma cell stemness by activating Notch signaling pathway.2021Bioengineered
  31. MicroRNA-629-5p promotes osteosarcoma proliferation and migration by targeting caveolin 1.2021Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
Earlier papers (2016–2020)20
  1. Proscillaridin A induces apoptosis and inhibits the metastasis of osteosarcoma in vitro and in vivo.2020Biochemical and biophysical research communications
  2. CDKN2B-AS1 Exerts Oncogenic Role in Osteosarcoma by Promoting Cell Proliferation and Epithelial to Mesenchymal Transition.2020Cancer biotherapy & radiopharmaceuticals
  3. Circ_0010220-mediated miR-503-5p/CDCA4 axis contributes to osteosarcoma progression tumorigenesis.2020Gene
  4. Hsa-let-7g promotes osteosarcoma by reducing HOXB1 to activate NF-kB pathway.2019Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  5. Relationship between red cell distribution width and prognosis of patients with osteosarcoma.2019Bioscience reports
  6. The Notch Pathway Promotes Osteosarcoma Progression through Activation of Ephrin Reverse Signaling.2019Molecular cancer research : MCR
  7. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.2019Molecular carcinogenesis
  8. Synergistic effect of docetaxel combined with cisplatin on inhibiting human osteosarcoma in nude mice.2018Biochemical and biophysical research communications
  9. LncRNA SNHG12 promotes tumorigenesis and metastasis in osteosarcoma by upregulating Notch2 by sponging miR-195-5p.2018Biochemical and biophysical research communications
  10. Cinobufagin Induces Apoptosis in Osteosarcoma Cells Via the Mitochondria-Mediated Apoptotic Pathway.2018Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  11. Peroxiredoxin 1 (PRDX1) Suppresses Progressions and Metastasis of Osteosarcoma and Fibrosarcoma of Bone.2018Medical science monitor : international medical journal of experimental and clinical research
  12. miR-143-3p inhibits the proliferation, migration and invasion in osteosarcoma by targeting FOSL2.2018Scientific reports
  13. Cinobufagin induces apoptosis of osteosarcoma cells through inactivation of Notch signaling.2017European journal of pharmacology
  14. SOX5 promotes epithelial-mesenchymal transition in osteosarcoma via regulation of Snail.2017Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  15. LncRNA-ANCR regulates the cell growth of osteosarcoma by interacting with EZH2 and affecting the expression of p21 and p27.2017Journal of orthopaedic surgery and research
  16. High CCL5 expression is associated with osteosarcoma metastasis and poor prognosis of patients with osteosarcoma.2017Molecular medicine reports
  17. MicroRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma.2017Molecular medicine reports
  18. Telomerase reverse transcriptase promotes chemoresistance by suppressing cisplatin-dependent apoptosis in osteosarcoma cells.2017Scientific reports
  19. Bispecific antibody suppresses osteosarcoma aggressiveness through regulation of NF-κB signaling pathway.2017Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  20. Cisplatin selects for stem-like cells in osteosarcoma by activating Notch signaling.2016Oncotarget

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 2 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

9 hospitals in Wuhan for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 10 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
10
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 5520232024: 1120242025: 002025

10 hospitals in Wuhan for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led10
  1. PERK inhibition mitigates acrylamide-induced tau phosphorylation and synaptic deficits via the GSK-3β and ATF4 pathways in human neuroblastoma SH-SY5Y cells.2026Ecotoxicology and environmental safety
  2. L116 Deletion in CSPα Promotes α-Synuclein Aggregation and Neurodegeneration.2024Molecular neurobiology
  3. Inhibition of PINK1-Mediated Mitophagy Contributes to Postoperative Cognitive Dysfunction through Activation of Caspase-3/GSDME-Dependent Pyroptosis.2023ACS chemical neuroscience
  4. Neuronal-specific TNFAIP1 ablation attenuates postoperative cognitive dysfunction via targeting SNAP25 for K48-linked ubiquitination.2023Cell communication and signaling : CCS
  5. Exposure to dithiocarbamate fungicide maneb in vitro and in vivo: Neuronal apoptosis and underlying mechanisms.2023Environment international
  6. SNAP25 ameliorates postoperative cognitive dysfunction by facilitating PINK1-dependent mitophagy and impeding caspase-3/GSDME-dependent pyroptosis.2023Experimental neurology
  7. Retinoic Acid Prevents α-Synuclein Preformed Fibrils-Induced Toxicity via Inhibiting STAT1-PARP1 Signaling.2023Molecular neurobiology
  8. Exposure to the environmentally toxic pesticide maneb induces Parkinson's disease-like neurotoxicity in mice: A combined proteomic and metabolomic analysis.2022Chemosphere
  9. Curcumin Attenuates the PERK-eIF2α Signaling to Relieve Acrylamide-Induced Neurotoxicity in SH‑SY5Y Neuroblastoma Cells.2022Neurochemical research
  10. Exploration of the molecular characteristics of the tumor-immune interaction and the development of an individualized immune prognostic signature for neuroblastoma.2021Journal of cellular physiology

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

6 hospitals in Wuhan for Ewing sarcoma134 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led no English-language PubMed papers on myasthenia gravis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

3 hospitals in Wuhan for myasthenia gravis89 hospitals in China for myasthenia gravis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06447597

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Wuhan, Xi'an, Zunyi

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 1 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

5 hospitals in Wuhan for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

9 hospitals in Wuhan for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 3 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.4%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 0020242025: 002025

6 hospitals in Wuhan for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 2 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

7 hospitals in Wuhan for Behçet disease139 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led no English-language PubMed papers on Alport syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Wuhan for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Analysis of ultrastructural features of glomeruli in different genotypic Alport syndrome].2019Zhonghua bing li xue za zhi = Chinese journal of pathology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

8 hospitals in Wuhan for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Wuhan for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 2 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 3.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

4 hospitals in Wuhan for familial adenomatous polyposis74 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Other diseases

Leber hereditary optic neuropathy

Leber 遗传性视神经病变

Led 2 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 3.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

3 hospitals in Wuhan for Leber hereditary optic neuropathy30 hospitals in China for Leber hereditary optic neuropathy

No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

武汉大学人民医院

Renmin Hospital of Wuhan University

武汉

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
RenMin Hospital of WuHan University; Renmin Hospital of WuhanUniversity; PET-CT/MRI Center Renmin Hospital of Wuhan University Wuhan; Qianjiang Hospital Affiliated to Renmin Hospital of Wuhan University; East Hospital of Renmin Hospital of Wuhan University; First Affiliated Hospital of Wuhan University; Hubei General Hospital; Hubei Provincial People's Hospital

Suggest a correctionDownload the data